UA130771U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography, determination of serum MTHFR C677T polymorphism in the blood, osteocalcin content, homocysteine, PSA. With homozygous carrier 677-TT and osteocalcin levels <12 ng / ml, homocysteine> 20 μmol / l, PSA> 6 mg / l predict the development of osteoarthrosis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV Сб677Т), the content of osteocalcin, homocysteine, C-reactive protein (CRP), and with homozygous carrier 677-

TT, the content of osteocalcin "12 ng/ml, homocysteine 220 μmol/l, SRP "b mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The content of osteocalcin, homocysteine, SRP is determined by the immunoenzymatic method. With homozygous carrier 677-TT, levels of osteocalcin "12 ng/ml, homocysteine 220 μmol/l, SRP "b mg/l predict the development of osteoarthritis.

An example of using the method

Patient K., 55 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, x-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of osteocalcin, homocysteine, SRP was determined by immunoenzymatic method. Homozygous carrier 677-TT was established.

Levels of osteocalcin - 7.5 ng/ml, homocysteine - 32 μmol/l, PSA - 15 mg/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Zo

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the MTNEV C677T gene, the content of osteocalcin, homocysteine, SRP, in the homozygous carrier of 677-HTT and osteocalcin levels of "12 ng/ml" are determined in the blood serum , homocysteine 220 μmol/l, SRP »b mg/l predict the development of osteoarthritis. 00 Computer keyboardG. Payalnikovo (00000000 Ministry of Economic Development and Trade of Ukraine, str. M. Hrushevsky, 12/2, m. Kyiv, 01008, Ukraine SE "Ukrainian Institute of Industrial Property", str. Glazunova, 1, m. Kyiv - 42, 01601